engine Protein Arrays

“To identify potential biomarkers associated with axial spondyloarthritis, we used the engine biomarker screening service. As a first step, we had the autoantibody profiles of 4 patients investigated. In the course of this investigation on UniPEx arrays, more than 50 potential antigens could be identified. A subarray was created for these candidates and in a second step, a larger number of patients could easily be testet. This allowed us, to further narrow down our potential biomarker candidates. These will now be validated in further studies on a different platform. The engine protein arrays are a great tool for broad biomarker screening in the field of autoimmune diseases. The engine team has supported us throughout the process and the screening service has allowed us to focus on our other projects in parallel with the testing.”

“We screened B-cell receptors of central nervous system lymphoma with UniPEx arrays and discovered potential biomarkers, which we have successfully validated with antigens expressed in eukaryontic cells. With the prompt assistance of the engine team, we were able to continue our validation experiments in an uncomplicated manner and look forward to presenting the results in a paper soon.”

“We used the protein macroarrays to screen for protein-protein interaction (PPI) partners using fluorophore-labelled peptide baits. This enabled us to identify the histone lysine N-methyltransferase EHMT2/G9a as an interaction partner and functional modulator of trans-activation domains of transcription factors of the C/EBP family (1). We have further extended these PPI screens on UniPEx Arrays and to differentially post-translationally modified (PTM) peptides as baits. Thereby, we could not only measure large numbers of protein interactions on approximately one-third of the proteome simultaneously, but also explore a protein´s interactome depending on defined PTM states (2). An advantage of this approach using UniPEx protein/peptide libraries was the presence of large amounts of unmodified pray protein (expressed in E. coli) in combination with a defined duplicate spotting pattern, which enables quick exclusion of false-positive interactions.”

“We used the hEXselect multiprotein-array to identify interaction partners of antisera directed to bacteria, which are suspected to cause schizophrenia in the offspring of mothers infected during early pregnancy. ( 1, 2) By this we could identify a handful of interesting candidate molecules which have later been functionally characterized. In the course of these experiments, the hEXselect multiprotein-array turned out to be a highly valuable tool that is comparably easy to handle, making the experimental procedures nearly as simple as a western blot! However, even more important for our project was the fact, that the cDNAs in the expression library used for this array, were derived from the frontal cortex of two human fetal brains of the late first and the early second trimester of pregnancy, thereby covering in terms of schizophrenia pathology almost perfectly the expression pattern during the most vulnerable phase of prenatal brain development.”

“To our experience, the protein arrays are super-informative and yield highly reproducible results specifically for biomarker discovery and validation. We have screened Testis, Fetal hEX1, UniPEx and hEXselect protein arrays to identify autologous antibodies specific to Small Cell Lung Cancer (SCLC), Non-small Cell Lung Cancer (NSLCL), Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Behcet’s disease and Neuromyelitis optica (NMO) in comparison with healthy controls. We were able to identify disease specific autologous antibodies and validate them via custom-made arrays. The nature and format of the protein arrays provided us the opportunity to develop a screening protocol by which we were able to generate signals in a broad dynamic range, obtain high signal/background and positive signal/negative signal ratios. Further, we could identify novel autologous antibodies which we will publish after validation with ELISA and Western blot.”